SinoMab BioScience (3681) Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
3681 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SinoMab BioScience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.44 |
| 52 Week High | HK$3.76 |
| 52 Week Low | HK$0.80 |
| Beta | 0.42 |
| 1 Month Change | -2.70% |
| 3 Month Change | -14.79% |
| 1 Year Change | 42.57% |
| 3 Year Change | -31.43% |
| 5 Year Change | -67.93% |
| Change since IPO | -76.00% |
Recent News & Updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Shareholder Returns
| 3681 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0% | -5.5% | -0.2% |
| 1Y | 42.6% | 121.8% | 31.5% |
Return vs Industry: 3681 underperformed the Hong Kong Biotechs industry which returned 121.8% over the past year.
Return vs Market: 3681 exceeded the Hong Kong Market which returned 31.5% over the past year.
Price Volatility
| 3681 volatility | |
|---|---|
| 3681 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in HK Market | 13.5% |
| 10% least volatile stocks in HK Market | 2.9% |
Stable Share Price: 3681 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3681's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 61 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus.
SinoMab BioScience Limited Fundamentals Summary
| 3681 fundamental statistics | |
|---|---|
| Market cap | HK$2.00b |
| Earnings (TTM) | -HK$161.61m |
| Revenue (TTM) | HK$6.41m |
Is 3681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3681 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.73m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥5.73m |
| Other Expenses | CN¥150.07m |
| Earnings | -CN¥144.34m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,520.34% |
| Debt/Equity Ratio | 145.7% |
How did 3681 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 21:43 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SinoMab BioScience Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue-Kwong Lui | Jefferies LLC |